Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells

Journal of Lipid Research

Volumn 51, Issue 8, 2010, Pages 2211-2222

  Zhang, Lin Hua ^a   Kamanna, Vaijinath S ^a   Ganji, Shobha H ^a   Xiong, Xi Ming ^a   Kashyap, Moti L ^a  

^a NONE

Author keywords

Atherosclerosis; Cholesterol; HDL metabolism; Nuclear receptors

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CULTURE MEDIUM; HIGH DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ARTICLE; CELL ADHESION; CELL STRAIN HEPG2; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; GENE DELETION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIVER CELL; MONOCYTE; MUTAGENESIS; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; AORTA; BIOSYNTHESIS; CHEMISTRY; CULTURE MEDIUM; CYTOLOGY; DNA RESPONSIVE ELEMENT; DRUG EFFECTS; GENETICS; HEPG2 CELL LINE; METABOLISM; NUCLEOTIDE SEQUENCE; PHARMACOLOGY;

AORTA; APOLIPOPROTEIN A-I; BASE SEQUENCE; CELL ADHESION; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL CELLS; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS, HDL; MONOCYTES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA; RESPONSE ELEMENTS; THIAZOLIDINEDIONES; TRANSCRIPTION, GENETIC;

EID: 77955589955     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M004481     Document Type: Article

References (30)

1. Wong, N. D., S. Malik, and M. L. Kashyap. 2005. Dyslipidemia. In Preventive Cardiology. N. D. Wong, H. R. Black, J. M., Gardin, editors. McGraw Hill Co., Inc., New York. 183-211.
2. Fielding, C. J., and P. E. Fielding. 1995. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36: 211-228.
3. Meyers, C. D., and M. L. Kashyap. 2005. Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. Curr. Opin. Cardiol. 20: 307-312.
4. Saku, K., M. Ahmed, P. Glas-Greenwalt, and M. L. Kashyap. 1985. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb. Res. 39: 1-8.
5. Banka, C. L. 1996. High density lipoprotein and lipoprotein oxidation. Curr. Opin. Lipidol. 7: 139-142.
6. Navab, M., S. S. Imes, S. Y. Hama, G. P. Hough, L. A. Ross, R. W. Bork, A. J. Valente, J. A. Berliner, D. C. Drinkwater, and H. Laks. 1991. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 88: 2039-2046.
7. Cockerill, G. W., K. A. Rye, J. R. Gamble, M. A. Vadas, and P. J. Barter. 1995. HDL inhibits cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15: 1987-1994.
8. Hofmann, C. A., and J. R. Colca. 1992. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care. 15: 1075-1078.
9. Van Wijk, J. P. H., E. J. P. de Koning, E. P. Martens, and T. J. Rabelink. 2003. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 23: 1744-1749.
10. Rosenblatt, S., B. Miskin, N. B. Glazer, M. J. Prince, and K. E. Robertson. 2001. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron. Artery Dis. 12: 413-423.
11. Gegick, C. G., and M. D. Altheimer. 2001. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr. Pract. 7: 162-169.
12. Kipnes, M. S., A. Krosnick, M. S. Rendell, J. W. Egan, A. L. Mathisen, and R. L. Schneider. 2001. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am. J. Med. 111: 10-17.
13. Einhorn, D., M. Rendell, J. Rosenzweigh, J. W. Egan, A. L. Mathisen, and R. L. Schneider. 2000. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The pioglitazone 027 Study Group. Clin. Ther. 22: 1395-1409.
14. Barbier, O., I. P. Torra, Y. Duguay, C. Blanquart, J. C. Fruchart, C. Glineur, and B. Staels. 2002. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22: 717-726.
15. Nagashima, K., C. Lopez, D. Donovan, C. Ngai, N. Fontanez, A. Bensadoun, J. Fruchart-Najib, S. Holleran, J. S. Cohn, R. Ramakrishnan, et al. 2005. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J. Clin. Invest. 115: 1323-1332.
16. Qin, S., T. Liu, V. S. Kamanna, and M. L. Kashyap. 2007. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha. Arterioscler. Thromb. Vasc. Biol. 27: 2428-2434.
17. Higuchi, K., S. W. Law, J. M. Hoeg, U. K. Schumacher, N. Meglin, and H. B. Jr. Brewer. 1988. Tissue-specific expression of apolipoprotein A-I (ApoA-I) is regulated by the 5′-flanking region of the human ApoA-I gene. J. Biol. Chem. 263: 18530-18536.
18. Widom, R. L., J. A. Ladias, S. Kouidou, and S. K. Karathanasis. 1991. Synergistic interactions between transcription factors control expression of the apolipoprotein AI gene in liver cells. Mol. Cell. Biol. 11: 677-687.
19. Mooradian, A. D., M. J. Haas, and N. C. Wong. 2004. Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes. 53: 513-520.
20. Delerive, P., C. M. Galardi, J. E. Bisi, E. Nicodeme, and B. Goodwin. 2004. Identification of liver receptor homolog-1 as a novel regulator of apolipoprotein AI gene transcription. Mol. Endocrinol. 18: 2378-2387.
21. Huuskonen, J., M. Vishnu, P. Chau, P. E. Fielding, and C. J. Fielding. 2006. Liver X receptor inhibits the synthesis and secretion of apolipoprotein A1 by human liver-derived cells. Biochemistry. 45: 15068-15074.
22. Sakamoto, J., H. Kimura, S. Moriyama, H. Odaka, Y. Momose, Y. Sugiyama, and H. Sawada. 2000. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem. Biophys. Res. Commun. 278: 704-711.
23. Chiquette, E., G. Ramirez, and R. Defronzo. 2004. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch. Intern. Med. 164: 2097-2104.
24. Szapary, P. O., L. T. Bloedon, F. F. Samaha, D. Duffy, M. L. Wolfe, D. Soffer, M. P. Reilly, J. Chittams, and D. J. Rader. 2006. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 26: 182-188.
25. Goldberg, R. B., D. M. Kendall, M. A. Deeg, J. B. Buse, A. J. Zagar, J. A. Pinaire, M. H. Tan, M. A. Khan, A. T. Perez, and S. J. Jacober. 2005. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 28: 1547-1554.
26. Davidson, M., P. M. Meyer, S. Haffner, S. Feinstein, R. Sr. D'Agostino, G. T. Kondos, A. Perez, Z. Chen, and T. Mazzone. 2008. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation. 117: 2123-2130. (Pubitemid 351572171)
27. Matsusue, K., M. Haluzik, G. Lambert, S. H. Yim, O. Gavrilova, J. M. Ward, B. Brewer, Jr., M. L. Reitman, and F. J. Gonzalez. 2003. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest. 111: 737-747.
28. Meyers, C. D., and M. L. Kashyap. 2004. Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection. Curr. Opin. Cardiol. 19: 366-373.
29. Jin, F. Y., V. S. Kamanna, and M. L. Kashyap. 1997. Niacin decreases removal of high density lipoprotein AI but not cholesterol ester by HepG2 cells. Arterioscler. Thromb. Vasc. Biol. 17: 2020-2028.
30. Eckland, D. A., and M. Danhof. 2000. Clinical pharmacokinetics of pioglitazone. Exp. Clin. Endocrinol. Diabetes. 108 ( Suppl. 2 ): S234-S242.